• Stamm

  Participated · Series A · Mar 2022

  Stämm develops a next-generation biomanufacturing platform that pairs naturally occurring microfluidics and laminar flow with 3D-printing to enable continuous and autonomous mammalian cell production. Led by CEO Yuyo Llamazares and based in Buenos Aires, the company employs a team of more than 100 people. Following its Series A, Stämm plans to prepare for commercialization and to further develop biopharma partnerships into pilot scale. The company will also use funds to enhance operational infrastructure, continue growing its team, and deepen its international presence. The article does not report revenue or other operating metrics.

• Stämm Biotech

  Participated · Series A · Feb 2022

  Stämm Biotech is building a desktop-sized bioreactor that 3D prints a dense network of microchannels to move cells through nutrients and oxygen, replacing tanks, stirrers and tubing. Its system is designed with a software component that configures channel designs and has been described as a “CDMO on the cloud.” The company says its approach can reduce the size of a biomanufacturing facility by two orders of magnitude and currently achieves outputs of about 30 liters, with a claimed potential to scale to roughly 5,000 liters. Commercialization is still early: Stämm is working with one European biopharma on biosimilars and has five potential partners in the pipeline, and it plans to move to pilot scale in 2022. Financially, Stämm closed a $17M Series A and has raised $20M in total (including prior seed and pre-seed rounds). The company is refining its microfluidic bioreactors and control tools, exploring business models, and plans to double headcount and expand internationally.

No current team members are available.